Search Results - "Chalermpalanupap, Natty"
-
1
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
Published in Journal of headache and pain (21-05-2024)“…Background Atogepant is an oral calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses…”
Get full text
Journal Article -
2
Change in Migraine Based on a Patient Global Impression of Change in Participants with Episodic Migraine and Chronic Migraine: Results from 5 Atogepant Clinical Trials (P8-12.006)
Published in Neurology (09-04-2024)“…Abstract only…”
Get full text
Journal Article -
3
Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)
Published in Neurology (25-04-2023)“…Abstract only…”
Get full text
Journal Article -
4
Benefit-risk assesment of atogepant: A post hoc anlysis of the advance trial
Published in Journal of the neurological sciences (01-12-2023)Get full text
Journal Article -
5
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
Published in Headache (01-11-2024)“…Objective To estimate the number needed to treat and cost per additional responder for atogepant and rimegepant versus placebo for the preventive treatment of…”
Get full text
Journal Article -
6
Focus on the Locus: Elucidating the Roles of Tau Pathology and the Locus Coeruleus in Alzheimer's Disease
Published 01-01-2017“…Alzheimer's disease (AD) is an insidious, progressive neurodegenerative disorder with societal and financial burdens that are escalating every single day…”
Get full text
Dissertation